Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.71 |
| ▸ | RRM1 | P23921 | 1/20 | 0.70 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.66 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.66 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.60 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.60 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248428 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL671932 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL15662048 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL506841 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL6419557 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL15662046 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL23001174 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL506842 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL21367553 | 1.00 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL506235 | 0.98 | DPP7 (0.69) | DPP7RRM1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | DPP7 2110/4885RRM1 2343/4885GNAI3 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.